We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aptevo Therapeutics Inc (APVO) USD0.001

Sell:$5.10 Buy:$5.50 Change: $0.29 (5.25%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Sell:$5.10
Buy:$5.50
Change: $0.29 (5.25%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Sell:$5.10
Buy:$5.50
Change: $0.29 (5.25%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company. The Company is focused on developing immunotherapeutic candidates for the treatment of different forms of cancer. The Company has two modular protein platforms of technology: ADAPTIR and ADAPTIR-FLEX. It is designed to generate monospecific, bispecific and multi-specific antibody candidates that are capable for the human immune system against cancer cells. The Company's lead product candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, are developed using the ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using the ADAPTIR-FLEX modular protein technology platform. APVO436 is a recombinant, bispecific T-cell engaging antibody candidate that is designed to target CD123, CD3 and redirect T-cell cytotoxicity to the tumor.

Contact details

Address:
2401 4th Ave Ste 1050
SEATTLE
98121-3460
United States
Telephone:
+1 (206) 8380500
Website:
aptevotherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
APVO
ISIN:
US03835L2079
Market cap:
$28.36 million
Shares in issue:
4.90 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.